Policy / Pricing FDA floats new clinical trial reforms; Takeda punts Denali brain drug pharminent April 6, 2026
M&A / Deals Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal pharminent April 6, 2026
Market Access The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun) pharminent April 6, 2026
Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer pharminent April 6, 2026
Policy / Pricing Trump revives pharma tariffs with 100% charges, but leaves loopholes pharminent April 3, 2026
Manufacturing BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot pharminent April 3, 2026
Policy / Pricing Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow pharminent April 3, 2026
M&A / Deals Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts pharminent April 3, 2026
Commercial Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences pharminent April 2, 2026
Policy / Pricing Rare Disease Leaders Call for Regulatory Clarity as FDA Balances Urgency With Rigor pharminent April 2, 2026
Market Access Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied pharminent April 2, 2026
Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH pharminent April 2, 2026
Policy / Pricing Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling pharminent April 2, 2026
Clinical Data Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment pharminent April 2, 2026
Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity pharminent April 2, 2026
Regulatory Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry pharminent April 2, 2026
Other Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26 pharminent April 2, 2026
M&A / Deals Biocytogen and Sihuan partner to advance new therapeutics for weight loss pharminent April 2, 2026
M&A / Deals Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets pharminent April 1, 2026
Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk pharminent April 1, 2026
Regulatory Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry pharminent April 1, 2026
Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program pharminent April 1, 2026
Clinical Data Viridian reports positive results from elegrobart phase 3 trial pharminent April 1, 2026
Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D pharminent April 1, 2026
M&A / Deals Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes pharminent April 1, 2026
M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B pharminent April 1, 2026
Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries pharminent April 1, 2026
